Hippocratic AI announced Polaris 6 Ultra on November 2, presenting a new generation of its conversational system for patient-facing healthcare workflows. The company says the agent can plan what to say next while speaking, adapt its voice to a patient's emotional cues and listen more reliably to difficult audio. The release also introduces Ultra, Pro, Flash and Nano configurations for different clinical and administrative workloads.
The company's headline 7.4-trillion-parameter figure describes the complete safety constellation, not a single monolithic model generating every sentence. Its main model has 671 billion parameters and operates alongside 30 specialist supervisors and 142 production monitors, according to the announcement. The supervisory components examine matters such as escalation, medication references, privacy and consent in parallel.
Hippocratic reports that its clinical speech-recognition system reduced misheard medications or symptoms from 1.19 to 0.20 per 100 calls in a review of 2,778 production conversations. It also reports a 1.3-fold end-to-end speed improvement over Polaris 5, and describes a 278-millisecond time to first sentence for the language-model component. These are specific company measurements with defined test conditions, not proof that every call will be safer or faster.
The model is designed for voice interactions such as follow-up and administrative support, not autonomous diagnosis or prescribing. The company says its systems have completed more than 250 million patient voice interactions and claims clinician-tested safeguards. Such aggregate usage and internal safety figures do not substitute for published independent clinical evaluations, patient-outcome studies or regulator determinations about a particular deployment.
The significance lies in the attempt to make agent systems responsive enough for natural healthcare conversations while adding a layered supervisory architecture. Hospitals and health systems considering deployment still need to examine consent, accessibility, audit trails, escalation to human clinicians and real-world error rates. The announcement establishes a product-generation change; it does not establish that the company's claimed clinical benefits have been independently reproduced.